Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
Part of Digestive system, Infections clinical trials.
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have chronic hepatitis B (positive HBsAg for more than 6 months).
- You were in a previous clinical trial for a hepatitis B RNA-targeting drug (ASO or siRNA) and your HBsAg level dropped by at least 10-fold.
- You cannot have taken interferon in the last 6 months.
- Your current HBsAg level must be between 1 and 500 IU/mL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
This study tests a new injection called AHB-137 combined with other hepatitis B drugs. It aims to see if the combination can better control the virus in people with chronic hepatitis B who are already on antiviral pills.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.